ArticleExperimental physiology2026
Cardioprotective effects of prolyl hydroxylase inhibitors during reperfusion in myocardial infarction: A study using cardiosphere-derived cells.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardioprotective effects of prolyl hydroxylase inhibitors during reperfusion in myocardial infarction: A study using cardiosphere-derived cells.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiosphere-derived cells (CDCs) are a promising in vitro model for studying myocardial ischaemia-reperfusion (I-R) injury and testing potential therapeutic interventions. This study investigated the suitability of CDCs as a model for myocardial infarction (MI) and the effects of prolyl hydroxylase inhibitor (PHI) administration during reperfusion. CDCs were generated from neonatal mouse hearts and characterized by immunofluorescence, revealing a heterogeneous mixture of cardiomyocytes, smooth muscle cells, endothelial cells, and stem cells. The CDCs were subjected to oxygen-glucose deprivation (OGD) followed by reperfusion with or without the PHI dimethyloxalylglycine (DMOG). Cell viability, hypoxia-inducible factor 1-alpha (HIF-1α) accumulation, and gene expression were analysed. The results showed that DMOG administration during reperfusion reduced lactate dehydrogenase release, indicating decreased cell death. HIF-1α protein levels increased during OGD and were further stabilized by DMOG during reperfusion. The expression of HIF-1α target genes, such as vascular endothelial growth factor (Vegfa), and genes involved in regeneration and cardiac function, including connective tissue growth factor (Ctgf), cyclin D2 (Ccnd2), and beta-1 adrenergic receptor (Adrb1), was modulated by OGD and DMOG treatment. Comparisons with an in vivo mouse I-R injury model revealed similarities in gene expression patterns. In conclusion, CDCs serve as an effective in vitro model for studying I-R injury, closely resembling the in vivo situation. Furthermore, PHI administration during reperfusion reduces cell death and modulates the expression of genes involved in cardioprotection and regeneration, highlighting the potential of PHIs as a therapeutic strategy for I-R injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.